| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
The primary target of Adrenocorticotropic Hormone (ACTH) (1-10) is the melanocortin 2 receptor (MC2R), a G protein-coupled receptor expressed primarily in the adrenal cortex. The full-length ACTH binds to MC2R and stimulates the production of cortisol and other glucocorticoids. The N-terminal region of ACTH is critical for receptor binding and activation, and the (1-10) fragment retains some of the receptor-binding properties of the full-length hormone. However, its affinity and potency are significantly lower than those of the full-length peptide due to the absence of the remaining amino acids.
|
|---|---|
| ln Vitro |
Alpha-melanocyte-stimulating hormone (MSH) stimulates differentiation of mouse epidermal melanocytes in vivo and in vitro. Adrenocorticotropic hormone (ACTH) has the same amino acid sequence as MSH [1].
In vitro, Adrenocorticotropic Hormone (ACTH) (1-10) is a fragment of the full-length ACTH that is used as a research tool to study the structure-activity relationships of ACTH and its receptor. The peptide's activity is related to its ability to bind to the melanocortin 2 receptor (MC2R), although its affinity and potency are lower than those of the full-length peptide due to the absence of the remaining amino acids. ACTH (1-10) is used in receptor binding studies to map the binding epitopes of ACTH and to identify the regions of the peptide that are critical for receptor interaction. |
| ln Vivo |
In vivo, ACTH is a peptide hormone produced by the anterior pituitary gland that stimulates the adrenal cortex to release cortisol and other glucocorticoids. As a fragment of ACTH, ACTH (1-10) may have some of these in vivo effects, although its potency is significantly reduced compared to the full-length peptide. The compound is used in research to study the metabolism and function of ACTH in vivo. It is also used as a standard in analytical methods for measuring ACTH and its metabolites in biological samples. Further in vivo studies are needed to fully characterize its biological activity.
|
| Enzyme Assay |
The in vitro binding activity of Adrenocorticotropic Hormone (ACTH) (1-10) can be assessed using receptor binding assays with the melanocortin 2 receptor (MC2R). A typical protocol involves incubating the peptide with membranes from cells expressing MC2R and a radiolabeled ACTH ligand (e.g., [125I]-ACTH). Bound and free ligand are separated by filtration, and the radioactivity is measured by gamma counting. The IC50 or Ki value is determined by plotting the percentage of specific binding remaining against the peptide concentration. The activity of the peptide can also be assessed using functional assays, such as measuring cAMP accumulation in cells expressing MC2R.
|
| Cell Assay |
For in vitro cellular experiments, cells expressing the melanocortin 2 receptor (e.g., adrenal cortical cells or transfected cell lines) are cultured in appropriate media and treated with ACTH (1-10) at various concentrations (typically 0.1-100 uM). The peptide's ability to activate the receptor is assessed by measuring downstream signaling, such as cAMP accumulation using ELISA or radioimmunoassay. The duration of treatment varies depending on the specific assay. The peptide can also be used in competition assays with full-length ACTH to determine its relative affinity and potency.
|
| Animal Protocol |
In vivo animal experiments with ACTH (1-10) are not commonly performed, as it is a fragment of ACTH. However, the peptide can be administered to animals (e.g., rats or mice) via intravenous or intraperitoneal injection to study its effects on cortisol production or other physiological parameters. A typical protocol involves administering the peptide at various doses and measuring plasma cortisol levels at various time points. Blood samples are collected to measure the levels of the peptide and its metabolites. The peptide is also used as a standard in analytical methods for measuring ACTH and its metabolites in biological samples.
|
| ADME/Pharmacokinetics |
Adrenocorticotropic Hormone (ACTH) (1-10) is a peptide with a molecular weight of approximately 1300 g/mol. As a peptide, its pharmacokinetic properties are characterized by rapid clearance from the circulation due to proteolytic degradation. The peptide is typically administered by injection in preclinical studies. Its half-life is short, and it is rapidly metabolized by peptidases in the blood and tissues. The peptide is stable in lyophilized form and should be stored at -20degC. It is soluble in aqueous buffers. Its pharmacokinetic properties make it suitable for acute pharmacological studies but less suitable for chronic dosing.
|
| Toxicity/Toxicokinetics |
Adrenocorticotropic Hormone (ACTH) (1-10) is a peptide fragment and is generally considered to have low toxicity. As a naturally occurring peptide fragment, it is expected to be well-tolerated at pharmacological doses. However, high doses may cause alterations in cortisol production or other physiological effects due to its interaction with MC2R. The compound should be handled with standard laboratory precautions and is intended for research use only.
|
| References | |
| Additional Infomation |
Adrenocorticotropic Hormone (ACTH) (1-10), human (CAS 2791-05-1) is a synthetic peptide corresponding to the first ten amino acids of human ACTH. The full-length ACTH is a 39-amino-acid peptide hormone produced by the anterior pituitary gland that stimulates the adrenal cortex to release cortisol. The N-terminal region (1-24) is essential for the biological activity of ACTH. ACTH (1-10) is a fragment that retains some receptor-binding properties and is used as a research tool to study the structure-activity relationships of ACTH and its receptor, the melanocortin 2 receptor (MC2R). It is available as a research compound and is not approved for clinical use.
|
| Molecular Formula |
C59H78N16O16S
|
|---|---|
| Molecular Weight |
1299.4132
|
| Exact Mass |
1298.55
|
| CAS # |
2791-05-1
|
| PubChem CID |
25084631
|
| Appearance |
White to off-white solid powder
|
| Density |
1.51g/cm3
|
| Index of Refraction |
1.693
|
| LogP |
1.548
|
| Hydrogen Bond Donor Count |
19
|
| Hydrogen Bond Acceptor Count |
20
|
| Rotatable Bond Count |
39
|
| Heavy Atom Count |
92
|
| Complexity |
2490
|
| Defined Atom Stereocenter Count |
9
|
| SMILES |
S(C([H])([H])[H])C([H])([H])C([H])([H])[C@@]([H])(C(N([H])[C@]([H])(C(N([H])[C@]([H])(C(N([H])[C@]([H])(C(N([H])[C@]([H])(C(N([H])[C@]([H])(C(N([H])C([H])([H])C(=O)O[H])=O)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12)=O)C([H])([H])C([H])([H])C([H])([H])/N=C(\N([H])[H])/N([H])[H])=O)C([H])([H])C1C([H])=C([H])C([H])=C([H])C=1[H])=O)C([H])([H])C1=C([H])N=C([H])N1[H])=O)C([H])([H])C([H])([H])C(=O)O[H])=O)N([H])C([C@]([H])(C([H])([H])O[H])N([H])C([C@]([H])(C([H])([H])C1C([H])=C([H])C(=C([H])C=1[H])O[H])N([H])C([C@]([H])(C([H])([H])O[H])N([H])[H])=O)=O)=O
|
| InChi Key |
DIBOMWBTHPDGOJ-YIXJHFLWSA-N
|
| InChi Code |
InChI=1S/C59H78N16O16S/c1-92-21-19-42(70-58(91)47(30-77)75-56(89)43(71-50(83)38(60)29-76)23-33-13-15-36(78)16-14-33)54(87)69-41(17-18-48(79)80)53(86)74-46(25-35-27-63-31-67-35)57(90)72-44(22-32-8-3-2-4-9-32)55(88)68-40(12-7-20-64-59(61)62)52(85)73-45(51(84)66-28-49(81)82)24-34-26-65-39-11-6-5-10-37(34)39/h2-6,8-11,13-16,26-27,31,38,40-47,65,76-78H,7,12,17-25,28-30,60H2,1H3,(H,63,67)(H,66,84)(H,68,88)(H,69,87)(H,70,91)(H,71,83)(H,72,90)(H,73,85)(H,74,86)(H,75,89)(H,79,80)(H,81,82)(H4,61,62,64)/t38-,40-,41-,42-,43-,44-,45-,46-,47-/m0/s1
|
| Chemical Name |
(4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-(carboxymethylamino)-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~192.40 mM)
H2O : ~2 mg/mL (~1.54 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (1.60 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (1.60 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (1.60 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.7696 mL | 3.8479 mL | 7.6958 mL | |
| 5 mM | 0.1539 mL | 0.7696 mL | 1.5392 mL | |
| 10 mM | 0.0770 mL | 0.3848 mL | 0.7696 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
